Ribociclib User Reviews & Ratings (Page 2)
Brand names: Kisqali
Ribociclib has an average rating of 8.3 out of 10 from a total of 30 reviews on Drugs.com. 81% of reviewers reported a positive experience, while 7% reported a negative experience.
Reviews for Ribociclib
- Anonymous
- Taken for less than 1 month
- February 26, 2021
Kisqali (ribociclib) for Breast Cancer, Metastatic "With Breast Cancer, Metastasis I am feeling very much better, while using Kisqali. But do have body pains but that can be manageable. Now I can easily run my job and home affairs."
- Samy
- Taken for less than 1 month
- December 4, 2019
For Breast Cancer, Metastatic "I have taken ribociclib for less than 10 days and develop a severe infection and very low white cells so I had to stay at hospital for 10 days to clear my infection"
- 123
- Taken for 1 to 6 months
- November 25, 2022
For Breast Cancer "2 cycles & tumour is spreading ....efficacy of drug not known"
- Anonymous
- Taken for 6 months to 1 year
- July 18, 2024
Kisqali (ribociclib) for Breast Cancer, Metastatic "Very few side effects. Have been able to continue golf, pickleball, bridge, and a nice social life. 600 mg per day for 3 weeks, then one week off."
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
More about ribociclib
- Check interactions
- Compare alternatives
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: CDK 4/6 inhibitors
- Breastfeeding
Kisqali (ribociclib) for Breast Cancer, Metastatic "Kisqali worked at first. All my numbers went down. Then they spiked up all at once."